×
About 1,354 results

ALLMedicine™ Fallopian Tube Cancer Center

Research & Reviews  653 results

The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930451
Journal of Gynecologic Oncology; Tokunaga H, Mikami M et. al.

Mar 2nd, 2021 - The fifth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was published in 2020. The guidelines contain 6 chapters-namely, (1) overview of th...

Clinical characteristics of primary Fallopian tube carcinoma: A single-institution retr...
https://doi.org/10.1002/ijgo.13497
International Journal of Gynaecology and Obstetrics: the ... Ma Z, Gao L et. al.

Nov 24th, 2020 - To analyze the clinical profile and prognosis of primary Fallopian tube cancer (PFTC) in order to improve earlier diagnosis. In this retrospective study, 57 women with PFTC were assessed from 2006 to 2016. Pathology, clinical index, recurrence, an...

Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum res...
https://doi.org/10.1136/ijgc-2020-001863
International Journal of Gynecological Cancer : Official ... Chelariu-Raicu A, Levenback CF et. al.

Oct 10th, 2020 - 50-70% of epithelial ovarian cancers overexpress epidermal growth factor receptor, and its expression has been correlated with poor prognosis. We conducted a phase Ib/II trial to examine the efficacy, safety, and toxicity of gefitinib, a tyrosine ...

Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community onco...
https://doi.org/10.1016/j.ygyno.2020.07.020
Gynecologic Oncology; Eakin CM, Ewongwo A et. al.

Aug 19th, 2020 - This study aims to describe the real-world experience, including the clinical and financial burden, associated with PARP inhibitors in a large community oncology practice. Retrospective chart review identified patients prescribed olaparib, nirapar...

see more →

Guidelines  3 results

Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
https://doi.org/10.1097/AOG.0000000000002296
Obstetrics and Gynecology;

Aug 23rd, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
https://doi.org/10.1097/AOG.0000000000002285
Obstetrics and Gynecology Reference;

Aug 23rd, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian canc...
https://doi.org/10.1007/s10147-016-0985-x
International Journal of Clinical Oncology; Komiyama S, Katabuchi H et. al.

May 4th, 2016 - The fourth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer was published in 2015. The guidelines contain seven chapters and six flow ...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  685 results

The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930451
Journal of Gynecologic Oncology; Tokunaga H, Mikami M et. al.

Mar 2nd, 2021 - The fifth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was published in 2020. The guidelines contain 6 chapters-namely, (1) overview of th...

Clinical characteristics of primary Fallopian tube carcinoma: A single-institution retr...
https://doi.org/10.1002/ijgo.13497
International Journal of Gynaecology and Obstetrics: the ... Ma Z, Gao L et. al.

Nov 24th, 2020 - To analyze the clinical profile and prognosis of primary Fallopian tube cancer (PFTC) in order to improve earlier diagnosis. In this retrospective study, 57 women with PFTC were assessed from 2006 to 2016. Pathology, clinical index, recurrence, an...

Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum res...
https://doi.org/10.1136/ijgc-2020-001863
International Journal of Gynecological Cancer : Official ... Chelariu-Raicu A, Levenback CF et. al.

Oct 10th, 2020 - 50-70% of epithelial ovarian cancers overexpress epidermal growth factor receptor, and its expression has been correlated with poor prognosis. We conducted a phase Ib/II trial to examine the efficacy, safety, and toxicity of gefitinib, a tyrosine ...

Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community onco...
https://doi.org/10.1016/j.ygyno.2020.07.020
Gynecologic Oncology; Eakin CM, Ewongwo A et. al.

Aug 19th, 2020 - This study aims to describe the real-world experience, including the clinical and financial burden, associated with PARP inhibitors in a large community oncology practice. Retrospective chart review identified patients prescribed olaparib, nirapar...

see more →

News  11 results

Ability to perform daily activities did not predict chemotherapy tolerability in elderly women
https://www.mdedge.com/hematology-oncology/article/81427/gynecologic-cancer/ability-perform-daily-activities-did-not
Sharon Worcester

Apr 2nd, 2014 - TAMPA – The ability to perform daily activities was not associated with the completion of chemotherapy without dose reduction or delay in elderly women with ovarian, primary peritoneal, or fallopian tube cancer. However, reporting limited social a.

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
https://www.mdedge.com/hematology-oncology/article/56300/gynecologic-cancer/bevacizumab-and-intravenous-or-intraperitoneal

Oct 17th, 2012 - Objectives: Bevacizumab (Avastin) and chemotherapy delivered through an intraperitoneal regimen can be highly effective, but also highly toxic. The primary outcomes of this study measure progression-free survival, but investigators will also be lo.

Bevacizumab: First-Line Therapy in Ovarian Cancer?
https://www.medscape.com/viewarticle/762036_2

Apr 18th, 2012 - Who Should Receive Bevacizumab? Dr. Markman. Thank you, Bob. If you don’t mind, I would like to have you answer several more questions before turning to Ken for his response. On the basis of the GOG-218[1] and ICON 7 trials,[2]which patients shoul...

Bevacizumab Plus Chemotherapy May Improve Overall Survival In High-Risk Ovarian Cancer
https://www.onclive.com/publications/obtn/2011/july-2011/bevacizumab-plus-chemotherapy-may-improve-overall-survival-in-high-risk-ovarian-cancer

Aug 1st, 2011 - Gunnar Kristensen, MD, PhD Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved overall survival (OS) in women with high-risk ovarian cancer, according to an interim survival analysis of the ICO...

Bevacizumab Benefits Patients With Recurrent Ovarian Cancer
https://www.staging.medscape.com/viewarticle/743996

Jun 4th, 2011 - June 5, 2011 (Chicago, Illinois) — Adding bevacizumab (Avastin) to chemotherapy appears to extend progression-free survival in women with recurrent ovarian cancer. According to data presented here at the American Society of Clinical Oncology 2011 ...

see more →